Clinical Trials Logo

Spondylitis clinical trials

View clinical trials related to Spondylitis.

Filter by:

NCT ID: NCT06185712 Completed - Clinical trials for Ankylosing Spondylitis

Patient Education in Ankylosing Spondylitis

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

This study was carried out to investigate the effect of a nurse-led disease management education program in AS on patient compliance, disease activity, functional capacity, kinesiophobia, and quality of life. A total of 122 patients diagnosed with AS according to the modified New York criteria were included in the study. The intervention group received nurse-led individualized disease management education. In the control group, no interventions were performed other than routine clinical procedures.

NCT ID: NCT06138717 Recruiting - Clinical trials for Axial Spondyloarthritis and Ankylosing Spondylitis

The Effect of Aerobic Exercises and Yoga Exercises in Axial Spondyloarthritis

Start date: November 18, 2022
Phase: N/A
Study type: Interventional

Axial Spondyloarthritis (AxSpA), mainly affecting the axial skeleton and sacroiliac joints, is a chronic, systemic, inflammatory disease that causes structural and functional disorders. Exercise has a significant role to play in managing treatments. This study aimed to determine the effect of yoga-based exercises combined with aerobic exercise on spinal mobility, disease activity and aerobic capacity in AxSpA.

NCT ID: NCT06114407 Recruiting - Clinical trials for Spondyloarthritis, Axial

Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

Start date: October 30, 2023
Phase: Phase 2
Study type: Interventional

Axial Spondylarthritis (ax-SpA) is an important cause of inflammatory back pain in young adults. Janus kinase inhibitors (JAKi) has been approved for treatment of ax-SpA. Tofacitinib and baricitinib are drugs from same family (JAKi). Baricitinib is relatively less expensive than Tofacitinib. The goal of this non-inferiority clinical trial is to learn about the efficacy of baricitinib in refractory axial spondyloarthritis ( ax-SpA) and to compare its effect with that of tofacitinib. The main questions it aims to answer are: 1. Is baricitinib 4 mg effective in refractory ax-SpA? 2. Is baricitinib non-inferior to tofacitinib in refractory ax-SpA? Participants (treatment group, 92 patients) will be treated with baricitinib 2 mg twice daily for 12 weeks. Ninety two patients getting tofacitinib 10 mg/day (comparison group) will be taken as historical control from another study on the efficacy of tofacitinib in refractory ax-SpA?

NCT ID: NCT06112665 Not yet recruiting - Clinical trials for Axial Spondyloarthritis

ToFAcitinib in Early Active Axial SpondyloarThritis:

FASTLANE
Start date: November 10, 2023
Phase: Phase 4
Study type: Interventional

This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an NSAID) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early active axSpA and inadequate response to at least one NSAID, with objective signs of inflammation.

NCT ID: NCT06094686 Completed - Clinical trials for Ankylosing Spondylitis

Epicardial Adipose Tissue Thickness and the Related Factors in Patients With Ankylosing Spondylitis

Start date: August 1, 2015
Phase:
Study type: Observational

The aim of this study was to assess the EATT and the related factors in patients with AS and to compare the results with that of the healthy controls'

NCT ID: NCT06094673 Completed - Clinical trials for Ankylosing Spondylitis

The Relationship Between Systemic Immune Inflammation Index and Disease Activity in Patients With Ankylosing Spondylitis

Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

In this study, the aim was to investigate the relationship between SII and other laboratory parameters with disease activity in AS patients and to discuss its usability in the follow-up and treatment process.

NCT ID: NCT06092775 Not yet recruiting - Vertebral Fracture Clinical Trials

Prevalence of Subclinical Vertebral Fractures in Rheumatoid Arthritis and Ankylosing Spondylitis

Start date: December 2023
Phase:
Study type: Observational

Study of prevalence of subclinical vertebral fractures in Rheumatoid Arthritis and Ankylosing spondylitis

NCT ID: NCT06085534 Completed - Clinical trials for Ankylosing Spondylitis

A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis

Start date: January 6, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study was to evaluate the safety and efficacy of multiple doses of LNK01001 monotherapy versus placebo in the treatment of adults with active Ankylosing Spondylitis

NCT ID: NCT06083090 Not yet recruiting - Clinical trials for Axial Spondyloarthritis (axSPA)

Effects of Yoga Therapy in Rehabilitation Compared to Physiotherapy in Moderate Axial Spondyloarthritis (axSPA)

YOKISPA
Start date: April 2024
Phase: N/A
Study type: Interventional

A few studies have evaluated the effectiveness of yoga therapy in patients with axial spondyloarthritis (axSPA). On the other hand, studies conducted in other chronic rheumatisms such as low back pain, rheumatoid arthritis or other conditions such as cancer have shown that yogatherapy can have a effective action on the physical and psychological level. Yogatherapy is a non-drug "body-mind" approach that would be likely to improve the physical symptoms (pain, stiffness, in particular spinal and pelvic), internal organs (colitis) and psychological symptoms as well as the perception of fatigue of people with axSPA. A 2021 study showed the feasibility and acceptability of regular yogatherapy practice in patients with axSPA. It is therefore necessary to conduct randomized controlled studies to assess the effectiveness of this management strategy.

NCT ID: NCT06077604 Not yet recruiting - Clinical trials for Spondyloarthritis, Axial

Influence of Air Pollution on SPondyloarthritis Flare-ups and Resistance to Treatment

SPAIR
Start date: October 15, 2023
Phase:
Study type: Observational

The relationship between exposure to air pollution and spondyloarthritis (SpA) has been poorly studied. Based on data from the literature on other inflammatory pathologies such as rheumatoid arthritis, we hypothesize that there is a relationship between exposure to air pollution and the risk of presenting a flare-up in SpA patients following and living in Franche-Comté (France). Primary objective:The potential relationship between exposure to air pollution (nitrogen dioxide, fine particles with a diameter of less than 10 or 2.5 microns and Ozone) and the onset of a spondyloarthritis flare-up will be explored in patients with this pathology.